103273-92-3

Basic information

• Product Name: 4-nitro-N-4-methyl-thiazol-2-yl-benzenesulfonamide
• Synonyms: 4-nitro-N-4-methyl-thiazol-2-yl-benzenesulfonamide
• CAS NO: 103273-92-3
• Molecular Weight: 299.331
• Mol File: 103273-92-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-nitro-N-4-methyl-thiazol-2-yl-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitro-N-4-methyl-thiazol-2-yl-benzenesulfonamide(103273-92-3)
• EPA Substance Registry System: 4-nitro-N-4-methyl-thiazol-2-yl-benzenesulfonamide(103273-92-3)

Safety Data

• Hazardous Substances Data: 103273-92-3(Hazardous Substances Data)

Upstream product

• 78-95-5 chloroacetone 
• 1603-91-4 4-methylthiazol-2-ylamine 
• 718604-49-0 4-nitro-benzenesulfenic acid-(4-methyl-thiazol-2-ylamide) 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 515-59-3 sulfamethylthiazole 

Relevant articles and documents

Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

Human lipoxygenases (LOXs) are a family of iron-containing enzymes which catalyze the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Our group has taken a particular interest in platelet-type 12-(S)-LOX (12-LOX) because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Herein, we report the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide-based scaffold. Top compounds, exemplified by 35 and 36, display nM potency against 12-LOX, excellent selectivity over related lipoxygenases and cyclooxygenases, and possess favorable ADME properties. In addition, both compounds inhibit PAR-4 induced aggregation and calcium mobilization in human platelets and reduce 12-HETE in β-cells.

In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidinand N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N 1propylglycinamide

A series of compounds containing the nitrobenzene and sulfonamido moieties were synthesized and their leishmanicidal effect was assessed in vitro against Leishmania infantum promastigotes. Among the compounds evaluated, the p-nitrobenzenesulfonamides 4Aa